 | |
| Company type | Public |
|---|---|
| ISIN | US74168J1016 |
| Industry | Biotechnology |
| Founded | 2019 |
| Founders |
|
| Headquarters | Cambridge, Massachusetts, U.S. |
Key people |
|
| Website | primemedicine |
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts. [1]
In May 2024, Prime Medicine announced that the U.S. FDA had accepted its IND application for PM359, a gene therapy involving transplantation of autologous CD34+ stem cells modified by prime editing ex vivo . [2] PM359 also received Rare Pediatric Disease and Orphan Drug designations from the FDA. A Phase 1/2 open-label clinical trial of PM359 in patients with chronic granulomatous disease (CGD) caused by mutations in the neutrophil cytosolic factor 1 (NCF1, also known as p47phox) gene began in October 2024, making PM359 the first prime editor to enter the clinic. [3] Following an announcement of preliminary results in May 2025, [4] Prime Medicine and its clinical collaborators reported in December 2025 that two CGD patients treated with PM359 had been "effectively cured" [5] of the disease. [6]
In May 2025, Prime Medicine announced that it would prioritize clinical development programs for the treatment of Wilson's disease and alpha-1 antitrypsin deficiency (AATD), two of the most common genetic liver diseases. [7]
In January 2024, Prime Medicine announced a partnership with the Cystic Fibrosis Foundation, with Prime Medicine receiving $15 million in funding towards the development of prime editing-based therapies for cystic fibrosis. [8] An additional $24 million commitment from the foundation was announced in July 2025. [9]
In September 2024, Prime Medicine announced a partnership with Bristol Myers Squibb to develop optimized prime editing reagents for ex vivo T cell therapies. Prime Medicine received $110 million upfront and is eligible for up to $3.5 billion in milestone payments. [10]